Subject: | |
From: | |
Reply To: | |
Date: | Wed, 4 Jun 1997 13:57:59 -0400 |
Content-Type: | TEXT/PLAIN |
Parts/Attachments: |
|
|
On Tue, 3 Jun 1997, Andrew S. Bonci, BA, DC, DAAPM wrote:
> > According to Barry Sears, this is the same problem that
> > accompanies the "therapeutic" use of flaxseed oil for its ALA
> > content. It supposedly downregulates D6D, so you get less of the
> > pro-inflammatory series 2 stuff, but you also get less of
> > everything else.
>
> Hmmm, I vaguely recall Sears' discussion on this topic. It's been a
> while since I read Sears.
From page 123 of _Enter the Zone_: "ALA is like a wet blanket
for the enzymes that control the eventual flow of omega-6
essential fatty acids toward eicosanoids. In many ways ALA is
the biological equivalent of aspirin: by limiting the activity of
the delta 6 desaturase enzyme, it knocks out the production of
both good and bad eicosanoids."
On the other hand, over on the Zone list there has been
discussion of a recent study that shows that ALA supplementation
offers significant protection against heart disease, and *not*
simply by acting as a precursor to EPA.
> > On a related subject, do you know any reason why saturated fats
> > would inhibit D6D? I have a chart in front of me that says they
> > do. If true, this would seem to be problematic.
>
> I am unaware of any reason unless you are talking transfatty acids; that
> being vegetable oils which have been hydrogenated. However, this
> stretches me a bit.
I am skeptical myself. If SFAs inhibit D6D and ALA inhibits D6D
and LA inhibits D6D and TFAs inhibit D6D then I think there are
some confounding variables floating around...
Todd Moody
[log in to unmask]
|
|
|